Skip to content

Search

Showing results for "lung disease preterm"

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Multiple sclerosis is a common disease of the central nervous system in which the interplay between inflammatory and neurodegenerative processes typically...

Eva

Eva Age 19. Youth advocate, Youth Advisory Group community member. I believe that research is an integral part of society and contributes to

Meningococcal vaccine provides extra protection for bubs

In 2017, a steep rise in cases of meningococcal disease caused by the W strain sparked a wave of concern for parents in Western Australia.

Evaluation of PLATINUM C: PLATform IN the Use of Medicines to treat chronic hepatitis C

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

FeBRILe3– Fever, Blood cultures and Readiness for discharge in Infants Less than 3 months’ old

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

Surveillance studies

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au Paediatric Active

Landmark $26m child health study eyes Wanneroo-Joondalup mums and dads

The Federal Government has joined with the Paul Ramsay Foundation to fund the project, with each pledging $13 million over 10 years.

A phase I clinical trial assessing the safety, tolerability, and pharmacokinetics of inhaled ethanol in humans as a potential treatment for respiratory tract infections

Current treatments for respiratory infections are severely limited. Ethanol's unique properties including antimicrobial, immunomodulatory, and surfactant-like activity make it a promising candidate treatment for respiratory infections if it can be delivered safely to the airway by inhalation. Here, we explore the safety, tolerability, and pharmacokinetics of inhaled ethanol in a phase I clinical trial.